A literature review and meta-analysis of drug company-funded mental health websites

Acta Psychiatrica Scandinavica

Volumn 128, Issue 6, 2013, Pages 422-433

  Read, J ^a   Cain, A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Drug industry; Internet; Mental health; Psychiatry

Indexed keywords

ANTIDEPRESSANT AGENT;

ADVERTIZING; ANOREXIA; ATTENTION DEFICIT DISORDER; COMPARATIVE STUDY; DEPRESSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; ERECTILE DYSFUNCTION; FUNDING; HUMAN; INTERNET; JAPAN; LIKERT SCALE; MEDICAL INFORMATION; MENTAL HEALTH; META ANALYSIS; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

DRUG INDUSTRY; INTERNET; MENTAL HEALTH; PSYCHIATRY;

DRUG INDUSTRY; HUMANS; INTERNET; MENTAL HEALTH; PATIENT EDUCATION AS TOPIC;

EID: 84887408501     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12146     Document Type: Review

References (42)

1. Bell R, Taylor D, Kravitz R. Do antidepressant advertisements educate consumers and promote communication between patients with depression and their physicians? Patient Educ Couns 2010;81:132-138.
2. Burns J, Davenport T, Durkin L, Luscombe G, Hickie I. The internet as a setting for mental health service utilisation by young people. Med J Aust 2010;192:56-62.
3. Khazaal Y, Chatton A, Cochand S et al. Internet use by patients with psychiatric disorders in search for general and medical information. Psychiatr Q 2008;79:301-309.
4. Powell J, Clarke A. Internet information-seeking in mental health: a population survey. Br J Psychiatry 2006;189:273-277.
5. Reavley N, Jorm A. The quality of mental disorder information websites: a review. Patient Educ Couns 2011;85:16-25.
6. Law J. Big Pharma: how the world's biggest drug companies control illness. London: Constable and Robinson, 2006.
7. Mosher L, Gosden R, Beder S. Drug companies and schizophrenia: unbridled capitalism meets madness. In: Read J, Mosher L, Bentall R, eds. Models of madness. London: Routledge, 2004:115-130.
8. Moncrieff J. Psychiatric drug promotion and the politics of neo-liberalism. Br J Psychiatry 2006;191:82-83.
9. Moynihan R, Cassels A. Selling sickness: how the world's biggest pharmaceutical companies are turning us all into patients. New York: Nation Books, 2005.
10. Sharfstein S. Big Pharma and American psychiatry: the good, the bad, and the ugly. Psychiatr News 2005;40:3-5.
11. Shooter M. Dancing with the devil? A personal view of psychiatry's relationships with the pharmaceutical industry. Psychiatr Bull 2005;29:81-83.
12. Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 2007;191:82-83.
13. Griffin M. DSM-V draft released, pharmaceutical industry influence questioned. http://scitechpolicy.wordpress.com/2010/02/16/dsm-v-draft-released-pharmaceutical-industry-influence-questioned/ February 16, 2010.
14. Foley S. GlaxoSmithKline pays $3bn for illegally marketing depression drug: doctors persuaded to prescribe drug later linked to suicide in children. The Independent 2012, July 3, P. 7.
15. Gilbody S, Wilson P, Watt I. Direct-to-consumer advertising: an emerging and evolving form of pharmaceutical company influence. Br J Psychiatry 2004;185:1-2.
16. Graber M, Weckmann M. Pharmaceutical company internet sites as sources of information about antidepressant medications. CNS Drugs 2002;16:419-423.
17. Woodlock D. Vitual pushers: antidepressant internet marketing and women. Women's Stud Int Forum 2005;28:304-314.
18. Nemoto K, Tachikawa H, Sodeyama N et al. Quality of Internet information referring to mental health and mental disorders in Japan. Psychiatry Clin Neurosci 2007;61:243-248.
19. De Wattignar S, Read J. The pharmaceutical industry and the internet: are drug-company funded depression websites biased? J Ment Health 2009;18:1-10.
20. Mansell P, Read J. Posttraumatic stress disorder, drug companies, and the internet. J Trauma Dissoc 2009;10:9-23.
21. Mitchell J, Read J. Attention-deficit hyperactivity disorder, drug companies and the internet. Clin Child Psychol Psychiatry 2012;17:121-139.
22. Read J. Schizophrenia, drug companies and the internet. Soc Sci Med 2008;6:99-109.
23. Read J, Mati E. Erectile dysfunction and the internet: drug company manipulation of public and professional opinion. J Sex Marital Ther 2013;39:541-559.
24. Cain A. Websites about anorexia: does drug company funding influence content? Unpublished honours dissertation, Psychology Department, University of Auckland, Doctorate of Clinical Psychology, 2010.
25. Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Stat Software 2010;36:1-15.
26. Akram G, Thomson A, Boyter A, Morton M. Characterisation and evaluation of UK websites on attention deficit hyperactivity disorder. Arch Dis Child 2008;93:695-700.
27. Khazaal Y, Chatton A, Zullino D, Khan R. HON Label and DISCERN as content quality indicators of health-related websites. Psychiatr Q 2012;83:15-27.
28. Zermatten A, Khazaal Y, Coquard O, Chatton A, Bondolfi G. Quality of web-based information on depression. Dep Anx 2010;27:852-858.
29. Lissman T, Boehnlein J. A critical review of internet information about depression. Psychiatr Serv 2002;52:1046-1050.
30. Read J, Haslam N, Sayce L, Davies E. Prejudice and schizophrenia: a review of the 'Mental illness is an Illness like any other' approach. Acta Psychiatr Scand 2006;114:303-318.
31. Read J, Magliano L, Beavan V. Public beliefs about the causes of 'schizophrenia': bad things happen and can drive you crazy. In: Read J, Dillon J, eds. Models of madness, 2nd edn. London: Routledge, 2013:143-156.
32. Schomerus G, Schwahn C, Holzinger A et al. Evolution of public attitudes about mental illness: a systematic review and meta-analysis. Acta Psychiatr Scand 2012;125:440-452.
33. Angermeyer M, Holzinger A, Carta M, Schomerus G. Biogenetic explanationsand public acceptance of mental illness. Br J Psychiatry 2011;199:367-372.
34. Read J, Haslam N, Magliano L. Prejudice, stigma and 'schizophrenia': the role of bio-genetic ideology. In: Read J, Dillon J, eds. Models of madness, 2nd edn. London: Routledge, 2013:157-177.
35. Read J, Bentall R. Negative childhood experiences and mental health: theoretical, clinical and primary prevention implications (editorial). Br J Psychiatry 2012;200:89-91.
36. Varese F, Smeets F, Drukker M et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull 2012;38:661-671.
37. Read J, Hammersley P, Rudegeair T. Why, when and how to ask about child abuse. Adv Psychiatr Treat 2007;13:101-110.
38. Hedman E, Andersson E, Ljotsson B et al. Clinical and genetic outcome determinants of Internet- and group-based cognitive behavior therapy for social anxiety disorder. Acta Psychiatr Scand 2012;126:126-136.
39. Hollandare F, Johnsson S, Randestad M et al. Randomized trial of Internet-based relapse prevention for partially remitted depression. Acta Psychiatr Scand 2011;124:285-294.
40. Consumer Reports. Free rein for drug ads? A slowdown in FDA review has left consumers more vulnerable to misleading messages. Consum Rep 2003;68:33-37.
41. Toop L, Richards D, Dowell T. The leadership role of general practice in public health: advocating a ban of direct-to-consumer advertising of prescription drugs in New Zealand. Br J Gen Pract 2003;53:342-345.
42. Usher W. Persuasion and types of enticements offered by pharmaceutical companies to Gold Coast general practitioners in an attempt to encourage a health website recommendation. Health Soc Care Community 2010;18:100-105.